PEGylation renders carnosine resistant to hydrolysis by serum carnosinase and increases renal carnosine levels

doi:10.21203/rs.3.rs-3984770/v1

Download PDF

Research Article

PEGylation renders carnosine resistant to hydrolysis by serum carnosinase and increases renal carnosine levels

https://doi.org/10.21203/rs.3.rs-3984770/v1

This work is licensed under a CC BY 4.0 License

You are reading this latest preprint version

Carnosine’s protective effect in rodent models of glycoxidative stress have provided a rational for translation of these findings in therapeutic concepts in patient with diabetic kidney disease. In contrast to rodents however, carnosine is rapidly degraded by the carnosinase-1 enzyme. To overcome this hurdle, we sought to protect hydrolysis of carnosine by conjugation to Methoxypolyethylene glycol amine (mPEG-NH₂). PEGylated carnosine (PEG-car) was used to study the hydrolysis of carnosine by human serum as well as to compare the pharmacokinetics of PEG-car and L-carnosine in mice after intravenous (IV) injection. While L-carnosine was rapidly hydrolyzed in human serum, PEG-car was highly resistant to hydrolysis. Addition of unconjugated PEG to carnosine or PEG-car did not influence hydrolysis of carnosine in serum. In mice PEG-car and L-carnosine exhibited similar pharmacokinetics in serum but differed in half-life time (t_1/2) in kidney, with PEG-car showing a significantly higher t_1/2 compared to L-carnosine. Hence, PEGylation of carnosine is an effective approach to prevent carnosine degradations and to achieve higher renal carnosine levels. However, further studies are warranted to test if the protective properties of carnosine are preserved after PEGylation.

L-carnosine

Diabetic nephropathy

PEGylated carnosine

Pharmacokinetics

L-carnosine, a natural histidine-containing dipeptide (HCD), is abundantly present in excitable tissues such as skeletal muscle and the central nervous system (CNS), while in non-excitable tissues carnosine levels are much lower(1). Although the physiological role of carnosine and other HCDs in kidney and other non-excitable tissues is subject of ongoing discussion, over the past decade carnosine has been reported to exert protective properties in an array of different disease models (2–10). Prompted by the finding that the carnosinase 1 gene (CNDP1) is a susceptibility locus for developing diabetic kidney disease (DKD) in patients with type 2 diabetes, various studies have reported possible mechanisms by which carnosine may convey protection against DKD (10–12). Also, small clinical trials using carnosine supplementation in obese patients have reported promising results (13–15). However, detection of serum carnosine after oral supplementation is only found in individuals with low carnosinase activity (16), suggesting that the efficacy of carnosine supplementation might be hampered by the action of the carnosine hydrolyzing enzyme serum carnosinase 1. Hence, carnosinase-resistant carnosine derivatives, e.g. D-carnosine-octylester (17) and, FL-926-16 ((2S)-2-(3-amino propanolamino)-3-(1H-imidazol-5-yl) propanol) (18), were developed and showed a good therapeutic efficacy in rodent models.

Polyethylene glycol (PEG) is an important excipient for drug delivery as it has no immunogenicity and has a high chemical stability and tolerability. These properties explain its wide use in different pharmaceutical formulations. Moreover, PEG based pharmaceutical formulations are approved by the US Food and Drug Administration (FDA) as drug delivery excipient in parenteral, topical, ophthalmic, oral and rectal administrations (19–21). PEGylation is mainly designed to improve drug solubility, stability and permeability (22) with linear PEG being the most widely used for drug delivery (23). Dependent of its molecular weight (MW), the physical states of PEG vary from clear liquids, soft solids to hard crystalline solids for PEG with low (100–700 kDa) intermediated (1000–2000 kDa) and high MW (> 2000 kDa) (24). Even so, PEG has high solubility in most of the organic as well as inorganic solvents due to its high polarity caused hydrophilicity (25). In most cases, PEG 2000 (kDa) has been the standard in the preparation of PEGylated liposomes (26–29).

Based on the advantages of PEG we sought to assess if PEGylation of carnosine (PEG-car) using methoxypolyethylene glycol amine (mPEG-NH₂) would render carnosine resistant to hydrolysis by carnosinase. We also performed a limited pharmacokinetic study to compare serum and renal t_1/2 for PEG-car and L-carnosine after an intravenous bolus injection in mice.

Synthesis of PEGylated Carnosine

Synthesis of mPEG-carnosine is shown in Fig. 1A and consisted of a sequential BOC-anhydride and amidation reactions. In brief, for the BOC-carnosine preparation, L-carnosine (10 g, 1 eq) (Sigma-Aldrich, St. Louis, MO, USA), NaOH (1.95 g, 1.1 eq), 100 mL of 1,4 dioxane (Hefei Baierdi Chemical Technology Co. Ltd, Hefei, China) and 100 mL deionized water were mixed in a round-bottom flask. BOC-anhydride (21 g, 2.2 eq) (Hefei Baierdi Chemical Technology Co. Ltd, Hefei, China), was added to the flask and continuously mixed overnight (16h) at 0℃. Hereafter, the mixture was concentrated up to dryness and the solid residue was extracted with 150 mL ethyl acetate followed by washing with 100 mL deionized water and 50 mL brine. The crude product was loaded on silica gel column (100–200 mesh, petroleum ether: ethyl acetate 5:1 as developing solvent). After elution, 12.5 g Boc-carnosine was yielded (yield, 66.3%).

For the Boc-carnosine-mPEG production, Boc-carnosine (3 g, 1 eq), linear chain methoxypolyethylene glycol amine with a molecular weight of 2000 kDa (mPEG-NH_2, 21.1 g, 1.5 eq) (Ponsure Company, Shanghai, China), O-(7-Azabenzotriazol-1-yl)-N, N, N', N'-tetramethyluronium hexafluorophosphate (HATU, 4 g, 1.5 eq) (Sigma-Aldrich, St. Louis, MO, USA), N, N-Diisopropylethylamine (DIPEA, 1.8 g, 2 eq) (Sigma-Aldrich, St. Louis, MO, USA) were dissolved in 50 mL N, N-Dimethylformamide (DMF) (Sigma-Aldrich, St. Louis, MO, USA) and stirred at room temperature for 16 h under nitrogen. The purity (> 95%) of mPEG-NH₂ was demonstrated by ¹H-NMR. HATU was used as dehydrating agent to activate carboxyl and promoted the formation of an ester bond. As an alkaline reagent, DIPEA was used as nucleophilic reagent and acid binding agent. On the next day, the mixture was concentrated and extracted by 150 mL ethyl acetate and then washed twice with 100 mL deionized water and twice with 50 mL brine. Afterwards, the crude products were loaded and purified on silica gel column (100–200 mesh, petroleum ether: ethyl acetate 10:1 as developing solvent). After elution, 15 g Boc-carnosine-mPEG was yielded (yield, 88.8%).

The eventual step is the conjugation of PEG and L-carnosine. In this case, Boc-carnosine-mPEG (15 g, 1 eq) was dissolved in 20 mL dioxane and then a mixture of 50 mL dioxane and hydrochloric acid was added. Hereafter, the mixture was concentrated in vacuum and subsequently loaded and purified on silica gel column (100–200 mesh, Dichloromethane: Methanol 10:1 as developing solvent) to harvest the white final compound, 5.9 g mPEG-carnosine (PEG-car) (yield, 42.9%).

Chemical Characterized Analysis of Synthesized PEG-car

¹H-NMR (Nuclear Magnetic Resonance Spectroscopy) was carried out to confirm PEGylation of L-carnosine. PEG-car was first dissolved in DMSO-d₆ (Sigma-Aldrich, St. Louis, MO, USA) and analyzed by Bruker AVANCE Ⅲ HD 400 NMR spectrometer (Bruker, Germany) at 400 MHz. The spectral processing with chemical shifts reported in part per million (ppm). The purity of target conjugate was characterized by Ultra-High Performance Liquid Chromatography Mass Spectrometry (UHPLC-MS; Shimadzu LCMS-2020, Japan). The samples were loaded on a chromatographic column (C18, 100 mm×4.6 mm, 5µm, Waters Sunfire, USA) and eluted in 13 minutes using a gradient elution containing 0.1% formic acid (J&K Chemical Ltd. Shanghai, China) in ultrapure water as, eluent A and acetonitrile containing 0.1% formic acid as eluent B. 10% eluent B was held for 2 min and the proportion was increased to 95% within 10 min. Hereafter, 95% eluent B was held for f 2min and the proportion went back to 10% within 0.01 min. with a flowrate of 1 mL/min The injection volume was 10 µL, the column temperature was maintained at 40°C. Conjugation of L-carnosine to mPEG-NH₂ was confirmed by matrix assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF; Bruker Daltonics, USA). The samples were dissolved in deionized water and 2,5-dihydroxy-benzoic acid (DHB) was used as assisted matrix.

Enzymatic Hydrolysis by Carnosinase-1

The resistance of the PEG-car to the enzymatic hydrolysis by carnosinase-1 was assayed by a previously designed enzymatic activity test (30). Briefly, PEG, PEG-car and L-carnosine (1 mM) respectively were incubated in Tris/HCl buffer (50 mM, pH 7.5) at 30°C with carnosinase-1 (recombinant Human CN-1, Novoprotein Company, Suzhou, China). Aliquots of each sample taken after 5, 10, 20, 30, 40, 60, 80 min, and the enzymatic reaction was stopped by addition of 50 µL of 1% trichloroacetic acid (TCA). After addition of 50 µL of 5 mg/mL o-pthaldialdehyde dissolved in 2 M NaOH and incubation for 30 min at 30°C, the amount of liberated histidine was quantified by fluorometric assay conducted by a multifunctional enzyme marker reader.

Kinetic Studies of PEG-car or L-carnosine in Mice

Six- to eight-week-old male C57BL/6J (20–25 g) mice were purchased from Sino-British SIPPR/BK Lab Animal Ltd (Shanghai, China). After ad libitum feeding for one week, the mice were randomly divided into three groups: the control group (n = 3, saline treated), the PEG-car treated group (n = 3) and the L-carnosine treated group (n = 3). Hereof, each mouse was respectively injected intravenously (i.v.) with saline, PEG-car (1000 mg/kg) or L-carnosine (1000 mg/kg) through the tail vein. The mice were anaesthetized by the inhalation of isoflurane during the injection. Blood samples were collected in EDTA tubes by cardiac puncture at 0, 5, 15, 30, 60, 120, 240 min after the administration of PEG-car or L-carnosine. Sera were obtained by centrifugation of the blood sample at 6800 g for 6 min at 4 ℃. Right after sacrifice, the mice were perfused by phosphate-buffered saline to remove the remaining blood. The brains and kidneys were carefully isolated thereafter. The tissues were stored at − 80 ℃and the sera were stored at − 20 ℃ untill use.

This animal study was approved by the Ethics Committee of Animal Research of Anhui Medical University (Hefei, China, No. LLSC20232088).

Determination of L-carnosine Levels by LC-MS/MS

PEG-car or L-carnosine levels in serum and tissues were determined by liquid chromatography tandem-mass spectrometry (LC-MS/MS). Warfarin (Sigma-Aldrich, St. Louis, MO, USA) was used as internal standard (IS). The entire procedure for sample and standard preparation was carried out on ice. An aliquot of 20 µL serum or homogenized 40 mg tissue were pipetted into centrifuge tube and then 400 µL methanol was added for protein precipitation. After spiking the IS (40 ng for serum and 4 ng for kidney), the samples were vortexed for 1 min and then centrifuged at 18000 g for 7 min at 4 ℃. The supernatant was used for the assay. The calibration curves were prepared by spiking the known concentrations of PEG-car or L-carnosine into serum or tissue homogenates obtained from untreated mice.

The concentrations were measured by a UHPLC system (Shimadzu LC-40D XS, Japan) coupled with electrospray ionization (ESI) and triple quadrupole-ion trap mass spectrometry (AB SCIEX QTRAP® 6500+, Singapore). PEG-car was performed in ACQUITY UPLC BEH C18 column (2.1 mm×50 mm, 1.7µm, Waters, USA) with a 0.6 mL/min flow rate of mobile phase using gradient elution of ultrapure water (2mM Ammonium acetate (Sinopharm Chemical Reagent Co., Ltd, Shanghai, China) containing 0.1% formic acid, eluent A) and acetonitrile (2mM Ammonium formate (Sinopharm Chemical Reagent Co., Ltd, Shanghai, China) containing 0.1% formic acid, eluent B). The solvent gradient was changed according to the following program: 0-0.01 min 10%B, 0.01–0.6 min 10%-90%B, 0.6–1.2 min 90%B, 1.2–1.21 min 90%-10%B, 1.21–1.5 min 10%B. L-carnosine was performed in ACQUITY UPLC BEH Amide column (2.1 mm×50 mm, 1.7µm, Waters, USA) with a 0.6 mL/min flow rate of mobile phase using gradient elution of ultrapure water (2mM Ammonium acetate containing 0.1% formic acid, eluent A) and acetonitrile (2mM Ammonium formate containing 0.1% formic acid, eluent B). The solvent gradient was as follows: 0-0.01 min 90%B, 0.01–0.6 min 90%-40%B, 0.6–1.2 min 40%B, 1.2–1.21 min 40%-90%B, 1.21–1.5 min 90%B. The injection volume was 5 µL. The QTRAP® 6500 + was operated in positive mode, multiple reaction monitoring (MRM) in unit resolution for Q1 and Q3. For detection of PEG-car, three transitions were set with a Q1 mass of 776.4, and Q3 masses of 109.9 (Collision Energy (CE) 119), 126.8 (CE 51), 707.2 (CE 38). For L-carnosine, four transitions were set with a Q1 mass of 227.3, and Q3 masses of 83.1 (CE 53), 110.0(CE 31), 156.2(CE 21), 210.2(CE 16). Pharmacokinetic parameters were calculated by noncompartmental analysis using a sparse sampling and naïve pooled approach (Phoenix WinNonLin 7.0, Certara, Mountain View, CA, USA).

Statistical analysis

All data are presented as means ± standard error of means (SEM) unless otherwise stated. Subgroup comparisons were analyzed using one-way ANOVA, followed by Tukey’s or Dunnett’s multiple-comparison test. The analysis was evaluated using GraphPad Prism 9.0 (GraphPad Software, Inc., La Jolla, California); p < 0.05 was considered statistically significant in all analyses.

Structural Characterization and Purity of PEG-car

As depicted in Fig. 1B, ¹H-NMR (DMSO-d₆, 400 MHz) δ (ppm): 8.85 (d, J = 6.8 Hz, 1H), 8.49 (s, 1H), 7.82 (d, J = 2.4 Hz, 1H), 7.33 (s, 3H), 7.29 (s, 1H) were attributed to the protons of imidazole and reactive hydrogen; 4.73 (s, 1H) and 3.82(s, 1H) were attributed to the methylene protons closed to imidazole; 3.66–3.62 (m, 182H), 3.56–3.54 (m, 5H), 3.48–3.44 (m, 3H) and 3.38 (s, 3H) were attributed to the methylene and terminal methoxy protons of mPEG-NH₂; 3.20–3.12 (m, 3H) and 2.76–2.62 (m, 2H) belonged to the methylene protons of 2-aminoacetamide and the Chiral neutral. As shown in LC-MS (Fig. 2), the purity is greater than 98.9% (ELSD) and 99.8% (PDA, λ = 214 nm). In the MALDI-TOF analysis, the molecular weight (MW) of PEG-car was 2200 kDa, which was close to the theoretical MW as depicted in Fig. 1C. All these characteristic peaks in ¹H-NMR spectrum as well as MALDI-TOF indicated the successful synthesis of PEG-car.

PEGylation renders carnosine resistant to Carnosinase mediated hydrolysis

To assess if PEG-car is resistant to carnosinase mediated hydrolysis, histidine release was assessed. To this end, PEG-car, L-carnosine, mPEG-HN₂, a mixture of L-carnosine with mPEG-NH₂ and a mixture of PEG-car with L-carnosine were incubated with recombinant CN-1 for various time intervals and histidine release during each incubation period was determined. As depicted in Fig. 3, no fluorescence was detected in the PEG-NH₂ sample, while fluorescence increased with time in the carnosine sample. Fluorescence was significantly blunted in the PEG-car sample, approximately six times lower than that of the carnosine sample or the sample containing the mixture of L-carnosine and PEG-NH₂, in addition, the activity of CN-1 cannot be inhibited by PEG-car.

Pharmacokinetic of PEG-car or L-carnosine in Serum and Kidney

We next assessed t_1/2 of PEG-car (1000 mg/kg) or L-carnosine (1000 mg/kg) in serum and kidney of mice after a single intravenous injection. Concentrations of PEG-car and L-carnosine were measured by LC-MS/MS and plotted against time (Fig. 4) for calculation of the area under the curve (AUC), peak concentration (Cmax), halve-life (t_1/2), clearance (CL) and steady state volume of distribution (Vss) for PEG-car and L-carnosine. As shown in Table 1 and Fig. 4, with exception of Vss, no differences between the two compounds were observed in serum, while in renal tissue t_1/2 and Vss of PEG-car were higher compared to L-carnosine.

Table 1

Pharmacokinetic analysis of PEG-car and carnosine in serum and kidney
		Half-Life (min)	C_max (µg/mL)	AUC (µg/mL·min)	CL (mL/min/kg)	Vss (mL/kg)
serum	PEG-car	32	2671	67730	14.84	294*
serum	L-carnosine	62	2862	64871	15.43	606
kidney	PEG-car	168*	3899^b*	173340^c*	3.47^d*	830^e*
kidney	L-carnosine	105	5912^b	518040^c	1.59^d	208^e
^b: ng/mg tissue; ^c: ng/mg tissue·min; ^d: g/min/kg; ^e: g/kg
*: p < 0.05, compared to L-carnosine group

carnosine is a bioactive peptide, which has the functions of buffering, antioxidation, anti-inflammation, scavenging free radicals, antiaging and preventing metabolic disorders (31, 32). However, the potential protective action of this dipeptide in human is hampered by the carnosine hydrolyzing carnosinase enzymes (CN-1 and CN-2). Human CNDP1 encodes the secreted serum CN-1 with high specificity for L-carnosine, whereas human CNDP2 encodes tissue and cytosolic CN-2 which is a ubiquitous dipeptidase (33). Both CN-1 and CN-2 can hydrolyze L-carnosine efficiently. Therefore, different derivatives of L-carnosine have been synthesized to retard or prevent carnosine the degradation (18, 34). This can be accomplished by inhibition of carnosinase activity (35) or by making carnosine derivates that are resistant to carnosinase mediated hydrolysis. PEGylation transforms physicochemical properties of parent molecules like molecular weight, size, hydrophilicity, conformation, steric hindrance, ionic properties and etc. which leads to altered elimination kinetics. This increases in molecular size helps bypass elimination from kidney through glomerular filtration. When the molecular weights are below 20000 kDa, the clearance by kidney predominates (36, 37).

The spectrum and the final MW of PEG-car as shown in Fig. 1 indicated the successful synthesis, however, with relatively low production ratio (only 42.9%, yield). A more suitable catalyst selection might increase the yield, but this must be proved in the future experiment.

Nevertheless, our study demonstrated that histidine was significantly less released from PEG-car than L-carnosine under the hydrolysis of CN-1 as shown in Fig. 3, which suggested the relatively higher enzymatic stability of PEG-car. In contrast, the simple spike of the PEG solution into L-carnosine did not prevent the breakdown of L-carnosine, which excluded the influence of PEG solution per se. The stability of PEG-car could be as a result of the steric hindrance by PEG which interferes with the interaction between L-carnosine and CN-1. In particular, the PEGylation of L-carnosine leads to a derivative that could not be recognized by the catalytic site of carnosinase, but it is a pity that PEG-car lacks the ability to inhibit enzyme activity.

Against our initial hypothesis, our study showed both PEG-car and L-carnosine had similar pharmacokinetic parameters in serum. This might be principally due to the varied distribution of CN-1, as the expression pattern of CNDP1 varies in humans and rodents. Human CNDP1 is expressed extensively in liver and secreted massively in serum, whereas in rodents CNDP1 is mainly expressed in kidney and is not secreted (38). The absence of serum CN-1 in mice signifies the lack hydrolysis of L-carnosine in serum and thus explaining why pharmacokinetic parameters for PEG-Car and L-carnosine were similar. This is in strong contrast to the kidney where significant differences between both compounds were noticed. Indeed, our data revealed that in kidney the t_1/2 and Vss of PEG-car were superior than that of L-carnosine. Besides, the comparable pharmacokinetic parameters in serum might also be partly owing to the limitations in our pharmacokinetic work. Although the measurements of PEG-car and L-carnosine in the plasma and kidney were made at different time points, each animal in the study provided a single plasma and kidney sample at each time point. In terms of these pharmacokinetic parameters, our study thereafter combined all the available data in a single analysis by making use of a naïve pooled and sparse sampling approach (39, 40). Unfortunately, variability cannot be assessed by naïve pooled approaches (40) which made it difficult to determine the variation of the pharmacokinetic parameters in each animal.

In addition, our data unexpectedly found that the Vss of L-carnosine was greater than that of PEG-car in serum, whilst AUC and the clearance were similar for the two compounds. The reasons for this difference are not clear, however could further be assessed in a dedicated future pharmacokinetic study which would allow a more comprehensive comparison.

Nevertheless, PEG-car was more resistant to CN-1 than L-carnosine in kidney. As a matter of fact, the role of CN-1 and L-carnosine in diabetic kidney diseases has already been verified by plenty of evidences. Diabetic patient with higher serum CN-1 concentration and activity are thought to be more susceptible to DN (41); vice versa, L-carnosine could retard DN development in diabetic mice (42, 43). Further studies using human CNDP1 transgenic ob/ob mice (43) which could express CN-1 in serum and kidney and thereby closely resembles overt human DN would be useful to further explore the efficacy of PEG-car as compared to L-carnosine.

In conclusion, our study for the first time designed and synthesized L-carnosine derivative, PEG-car, and confirmed that PEG-car had strong resistance to CN-1. We also preliminarily evaluated the pharmacokinetics of PEG-car and L-carnosine in mice. hCNDP1 transgenic mice are warranted anyway to investigate the efficacy of PEG-car as compared to L-carnosine in DN.

Author Contribution

All authors contributed to the study conception and design. SZ and GZ conceived the initial experimental conception and design; GY, QZ, YF and MT performed material preparation, data collection and analysis; GY wrote the draft of the manuscript; BY revised the manuscript critically for important intellectual content; DZ, LS and GZ helped perform the analysis with constructive discussions. All authors commented on previous versions of the manuscript. All authors read and approved the fnal manuscript.

Van der Stede T, Spaas J, de Jager S, De Brandt J, Hansen C, Stautemas J, et al. Extensive profiling of histidine-containing dipeptides reveals species- and tissue-specific distribution and metabolism in mice, rats, and humans. Acta Physiol (Oxf). 2023:e14020.
Zhao J, Shi L, Zhang LR. Neuroprotective effect of carnosine against salsolinol-induced Parkinson's disease. Exp Ther Med. 2017;14(1):664-70.
Busa P, Lee SO, Huang N, Kuthati Y, Wong CS. Carnosine Alleviates Knee Osteoarthritis and Promotes Synoviocyte Protection via Activating the Nrf2/HO-1 Signaling Pathway: An In-Vivo and In-Vitro Study. Antioxidants (Basel). 2022;11(6).
Yang H, Hou X, Xing L, Tian F. Carnosine and bone (Review). Mol Med Rep. 2023;27(1).
Alsheblak MM, Elsherbiny NM, El-Karef A, El-Shishtawy MM. Protective effects of L-carnosine on CCl4 -induced hepatic injury in rats. Eur Cytokine Netw. 2016;27(1):6-15.
Caruso G, Fresta CG, Grasso M, Santangelo R, Lazzarino G, Lunte SM, et al. Inflammation as the Common Biological Link Between Depression and Cardiovascular Diseases: Can Carnosine Exert a Protective Role? Curr Med Chem. 2020;27(11):1782-800.
Sun C, Wu Q, Zhang X, He Q, Zhao H. Mechanistic Evaluation of the Protective Effect of Carnosine on Acute Lung Injury in Sepsis Rats. Pharmacology. 2017;100(5-6):292-300.
Miceli V, Pampalone M, Frazziano G, Grasso G, Rizzarelli E, Ricordi C, et al. Carnosine protects pancreatic beta cells and islets against oxidative stress damage. Mol Cell Endocrinol. 2018;474:105-18.
Peters V, Yard B, Schmitt CP. Carnosine and Diabetic Nephropathy. Curr Med Chem. 2020;27(11):1801-12.
Liu XQ, Jiang L, Lei L, Nie ZY, Zhu W, Wang S, et al. Carnosine alleviates diabetic nephropathy by targeting GNMT, a key enzyme mediating renal inflammation and fibrosis. Clin Sci (Lond). 2020;134(23):3175-93.
Zhu W, Li YY, Zeng HX, Liu XQ, Sun YT, Jiang L, et al. Carnosine alleviates podocyte injury in diabetic nephropathy by targeting caspase-1-mediated pyroptosis. Int Immunopharmacol. 2021;101(Pt B):108236.
Boldyrev AA, Aldini G, Derave W. Physiology and pathophysiology of carnosine. Physiol Rev. 2013;93(4):1803-45.
de Courten B, Jakubova M, de Courten MP, Kukurova IJ, Vallova S, Krumpolec P, et al. Effects of carnosine supplementation on glucose metabolism: Pilot clinical trial. Obesity (Silver Spring). 2016;24(5):1027-34.
Houjeghani S, Kheirouri S, Faraji E, Jafarabadi MA. l-Carnosine supplementation attenuated fasting glucose, triglycerides, advanced glycation end products, and tumor necrosis factor-alpha levels in patients with type 2 diabetes: a double-blind placebo-controlled randomized clinical trial. Nutr Res. 2018;49:96-106.
Menon K, Mousa A, de Courten B. Effects of supplementation with carnosine and other histidine-containing dipeptides on chronic disease risk factors and outcomes: protocol for a systematic review of randomised controlled trials. BMJ Open. 2018;8(3):e020623.
Everaert I, Taes Y, De Heer E, Baelde H, Zutinic A, Yard B, et al. Low plasma carnosinase activity promotes carnosinemia after carnosine ingestion in humans. Am J Physiol Renal Physiol. 2012;302(12):F1537-44.
Vistoli G, Orioli M, Pedretti A, Regazzoni L, Canevotti R, Negrisoli G, et al. Design, synthesis, and evaluation of carnosine derivatives as selective and efficient sequestering agents of cytotoxic reactive carbonyl species. ChemMedChem. 2009;4(6):967-75.
Iacobini C, Menini S, Blasetti Fantauzzi C, Pesce CM, Giaccari A, Salomone E, et al. FL-926-16, a novel bioavailable carnosinase-resistant carnosine derivative, prevents onset and stops progression of diabetic nephropathy in db/db mice. Br J Pharmacol. 2018;175(1):53-66.
Gullapalli RP, Mazzitelli CL. Polyethylene glycols in oral and parenteral formulations--A critical review. Int J Pharm. 2015;496(2):219-39.
D'Souza A A, Shegokar R. Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications. Expert Opin Drug Deliv. 2016;13(9):1257-75.
Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today. 2005;10(21):1451-8.
Abet V, Filace F, Recio J, Alvarez-Builla J, Burgos C. Prodrug approach: An overview of recent cases. Eur J Med Chem. 2017;127:810-27.
Kadajji VG, Betageri GV. Water Soluble Polymers for Pharmaceutical Applications. Polymers. 2011;3(4):1972-2009.
Thomas A, Muller SS, Frey H. Beyond poly(ethylene glycol): linear polyglycerol as a multifunctional polyether for biomedical and pharmaceutical applications. Biomacromolecules. 2014;15(6):1935-54.
Pasut G, Veronese FM. State of the art in PEGylation: the great versatility achieved after forty years of research. J Control Release. 2012;161(2):461-72.
Saw PE, Park J, Lee E, Ahn S, Lee J, Kim H, et al. Effect of PEG pairing on the efficiency of cancer-targeting liposomes. Theranostics. 2015;5(7):746-54.
Luk BT, Fang RH, Zhang L. Lipid- and polymer-based nanostructures for cancer theranostics. Theranostics. 2012;2(12):1117-26.
Nie Y, Ji L, Ding H, Xie L, Li L, He B, et al. Cholesterol derivatives based charged liposomes for doxorubicin delivery: preparation, in vitro and in vivo characterization. Theranostics. 2012;2(11):1092-103.
Qhattal HS, Hye T, Alali A, Liu X. Hyaluronan polymer length, grafting density, and surface poly(ethylene glycol) coating influence in vivo circulation and tumor targeting of hyaluronan-grafted liposomes. ACS Nano. 2014;8(6):5423-40.
Lenney JF, George RP, Weiss AM, Kucera CM, Chan PW, Rinzler GS. Human serum carnosinase: characterization, distinction from cellular carnosinase, and activation by cadmium. Clin Chim Acta. 1982;123(3):221-31.
Boldyrev AA, Aldini G, Derave W. Physiology and pathophysiology of carnosine. Physiol Rev. 2013;93(4):1803-45.
Kilis-Pstrusinska K. Carnosine and Kidney Diseases: What We Currently Know? Curr Med Chem. 2020;27(11):1764-81.
Teufel M, Saudek V, Ledig JP, Bernhardt A, Boularand S, Carreau A, et al. Sequence identification and characterization of human carnosinase and a closely related non-specific dipeptidase. J Biol Chem. 2003;278(8):6521-31.
Kulikova OI, Stvolinsky SL, Migulin VA, Andreeva LA, Nagaev IY, Lopacheva OM, et al. A new derivative of acetylsalicylic acid and carnosine: synthesis, physical and chemical properties, biological activity. Daru. 2020;28(1):119-30.
Qiu J, Hauske SJ, Zhang S, Rodriguez-Nino A, Albrecht T, Pastene DO, et al. Identification and characterisation of carnostatine (SAN9812), a potent and selective carnosinase (CN1) inhibitor with in vivo activity. Amino Acids. 2019;51(1):7-16.
Yamaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharm Sci. 1994;83(4):601-6.
Yamaoka T, Tabata Y, Ikada Y. Comparison of body distribution of poly(vinyl alcohol) with other water-soluble polymers after intravenous administration. J Pharm Pharmacol. 1995;47(6):479-86.
Pandya V, Ekka MK, Dutta RK, Kumaran S. Mass spectrometry assay for studying kinetic properties of dipeptidases: characterization of human and yeast dipeptidases. Anal Biochem. 2011;418(1):134-42.
Mahmood I. Naive pooled-data approach for pharmacokinetic studies in pediatrics with a very small sample size. Am J Ther. 2014;21(4):269-74.
KuKanich B, Huff D, Riviere JE, Papich MG. Naive averaged, naive pooled, and population pharmacokinetics of orally administered marbofloxacin in juvenile harbor seals. J Am Vet Med Assoc. 2007;230(3):390-5.
Janssen B, Hohenadel D, Brinkkoetter P, Peters V, Rind N, Fischer C, et al. Carnosinase Gene-Is It Responsible for Diabetic Nephropathy?: Carnosine as a Protective Factor in Diabetic Nephropathy: Association with a Leucine Repeat of the Carnosinase Gene CNDP1. Diabetes 54: 2320-2327, 2005. J Am Soc Nephrol. 2005;16(10):2823-6.
Sauerhofer SJ, Lammert A, Koppel H, Hammes HP, Kramer BK. Mixed messages on systemic therapies for diabetic retinopathy. Lancet. 2010;376(9751):1461; author reply 2.
Qiu J, Albrecht T, Zhang S, Hauske SJ, Rodriguez-Nino A, Zhang X, et al. Human carnosinase 1 overexpression aggravates diabetes and renal impairment in BTBR(Ob/Ob) mice. J Mol Med (Berl). 2020;98(9):1333-46.

No competing interests reported.

Download PDF

Editorial decision: Revision requested
03 Jun, 2024
Reviews received at journal
03 Apr, 2024
Reviewers agreed at journal
13 Mar, 2024
Reviewers invited by journal
27 Feb, 2024
Editor assigned by journal
26 Feb, 2024
Submission checks completed at journal
26 Feb, 2024
First submitted to journal
24 Feb, 2024

You are reading this latest preprint version

PEGylation renders carnosine resistant to hydrolysis by serum carnosinase and increases renal carnosine levels

Status:

Version 1

Abstract

Figures

Introduction

Materials and Methods

Synthesis of PEGylated Carnosine

Chemical Characterized Analysis of Synthesized PEG-car

Enzymatic Hydrolysis by Carnosinase-1

Kinetic Studies of PEG-car or L-carnosine in Mice

Determination of L-carnosine Levels by LC-MS/MS

Statistical analysis

Results

Structural Characterization and Purity of PEG-car

PEGylation renders carnosine resistant to Carnosinase mediated hydrolysis

Pharmacokinetic of PEG-car or L-carnosine in Serum and Kidney

Discussion

Declarations

Author Contribution

References

Additional Declarations

Status:

Version 1